Eunion Officially Establishes Global Foundation

New York, NY,October11, 2022- (SEAPRWire) – Recently, Eunion is pleased to announce that with the joint efforts and coordination of many parties, the Eunion Global Foundation was officially established. This is an important step for Eunion to go international, and it is also a milestone in Eunion’s global process. The establishment of Eunion Global Foundation enables Eunion to fully guarantee the development of marketization, specialization, and compliance. The Eunion trading team was established in 2013. The company originated in Europe. The team is committed to clearing transactions in the traditional financial (securities, stocks, foreign exchange) field. The team designs and develops trading programs and actually operates to obtain stable income from clearing transactions. Eunion has EU regulatory license MTR (digital currency transaction service license number: FRK000990, digital currency wallet service license number: FVR001101), US regulatory license MSB (license number: 31000164318323), Australian AUSTRAC license (regulatory number: DCE100666271-001) as solid backing. At the same time, it has gained multiple honors around the world, including the “WBC Global Partner Certificate”, “Best Fintech Technology” and so on. At present, 132 exchanges have been connected through an efficient matching engine, including digital currency, traditional securities, US stocks, Hong Kong stocks, A-shares, gold trading, etc. Eunion takes advantage of the speed of ultra-high-frequency trading to place a large number of orders for clearing transactions through automated procedures, and obtain high returns. At the same time, Eunion also combines the advantages of decentralized exchanges to provide users with a channel to link exchanges and act as an asset custody institution in the exchange to solve the transparency problem of asset management in the blockchain industry. With the continuous development and growth of Eunion and the increasing needs of customers, the diversification of projects and the efficiency of services have become rigid needs. In particular, there is a need for an efficient and transparent organization such as the Foundation to provide self-monitoring guarantees. Through the foundation, more talents, resources, and users can be aggregated and linked for Eunion, and the resources of the foundation can be mobilized to respond to the emerging needs of individualization, diversification, urgency, and internationalization. Based on this, Eunion established the Eunion Global Foundation and positioned it as a non-profit organization. Its responsibility is to focus on promoting the diversity of Eunion products, improving service efficiency, making Eunion more international, actively embracing future supervision, improving Eunion’s popularity and influence in the industry, and making Eunion’s financial framework more comprehensive. An excellent foundation must keep pace with the times, especially in the form of operation iteratively. Therefore, Eunion Global Foundation will continue to explore a more effective organizational structure and service model in the future to optimize the external and internal governance mechanisms. Eunion Global Foundation is committed to building the entire community through the core concepts of fairness, openness, co-construction, sharing, and transparency. As well as a strong and well-established relationship with the public, it can fully play a role as a bridge for the development of business globalization. Media Contact Company: Eunion Contact: Media Contact Email: info@eunion.ai Website: https://eunion.trade/ SOURCE: Eunion The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)

SINGAPORE ANNUAL MEETING: DIA and CoRE Gathering Key Healthcare Experts in Neutral Forum to Discuss Regulatory News and Drug Development

Singapore, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - The COVID-19 pandemic has ushered an increased speed of healthcare innovations with the hope of effectively managing this public health threat. This meeting offers a neutrally organized forum to discuss lessons learned and better prepare the healthcare system for the next challenges. From 12-13 July, representatives from Regulatory agencies, health authorities (Ali Al dalaan,[SFDA] Wen-Yi Hung[TFDA] Shin-ichi Okudaira [PMDA]) Jesusa Joyce N. CIRUNAY [Philippines FDA] and industry leaders (Serena Chan [Syneos Health], Daniela Caiazza [Novotech], Ralf Altenburger[Roche], Yu LIANG [MSD], and many more) meet in person for the first time in two years to foster positive changes in the healthcare environment in the Asia-Pacific. That includes emerging technologies, innovations in cancer care, digital health and improved patient access to novel therapies.Sessions discussing Digital Health, Decentralized Clinical Trials, and access to Innovative TherapiesConnecting different perspectives and interests in a neutral forum allows an open dialogue and facilitates solutions and concrete action points for today's healthcare challenges, such as:Fostering digital health adoption in the Asia-Pacific is highly dependent on regulatory frameworks. The session will discuss benefits of digital health, personalised care and what is necessary to improve application in the region. The dynamics of decentralised clinical trials has the potential to improve patients' experience. Serena Chan (Syneos Health Singapore), Daniela Caiazza (Novotech), and Jerome Armellini (IQVIA Singapore) will discuss how decentralised trials can benefit patients, clinicians, trial sites and sponsors beyond the pandemic setting.Novel approaches for managing cancer come from innovative cell and gene therapies. Challenges arise when it comes to country-specific regulations. Together with other specialists, Ralf Altenburger (Global Head Cell and Gene Therapy, F. Hoffmann La-Roche) will present where the field is going as an integral part of cancer care.Building regulatory agility for improved patient access became more aware throughout the pandemic. Ali Al dalaan (SFDA) will present his view on regulatory convergence and discuss with industry leaders how to improve patient access through regulatory agility.Empowering the ASEAN patients is subject of a townhall format, where all participants wrap up the conference and discuss the efficiency and sustainability of healthcare systems in ASEAN and identify next steps.About DIA Singapore Annual MeetingDate: 12-13 July 2022Location: Grand Copthorne Waterfront Hotel, SingaporeHavelock RoadSingapore 169663SingaporeRegistration information:Register before the 30th of June and get a 25% discount using the following code: SAM2022- Register online here: https://bit.ly/3aPsB9o- Register with one of our Team member: kanchan.patel@DIAglobal.orgAbout DIADIA (founded as the Drug Information Association) is a global association that mobilizes life science professionals from across all areas of expertise to engage with patients, peers, and thought leaders in a neutral environment on the issues of today and the possibilities for tomorrow. As a member-driven, volunteer organization, professionals from 80 countries have affected healthcare outcomes, by engaging with DIA through an unparalleled network, educational offerings, and professional development opportunities.DIA is based in Washington, DC (US) with regional offices representing the Americas (Horsham, PA, US); Europe, the Middle East, and Africa, (Basel, Switzerland); and Asia (Beijing and Shanghai, China; Mumbai, India; and Tokyo, Japan). Connect with DIA:Twitter: https://twitter.com/DrugInfoAssnLinkedIn: www.linkedin.com/company/diaFacebook: www.facebook.com/DrugInformationAssociation/Instagram: www.instagram.com/druginfoassn/About Centre of Regulatory Excellence (CoRE):Launched in 2014, CoRE at Duke-NUS Medical School, is the first dedicated Asian centre targeted at addressing the capacity development and policy innovation needs of national health regulators, the biomedical industry, and pharmaceutical and medical device companies. The Centre provides a neutral academic platform to establish regional platforms and networks to exchange knowledge, encourage innovation, promote thought leadership and collaboration in strengthening regulatory science and policy, and health systems frameworks, within and among national regulatory agencies, industry, health ministries and academia.Contact:CoRESherna WADIA Associate DirectorCentre of Regulatory ExcellenceDuke-NUS Medical SchoolEmail: core@duke-nus.edu.sgDIA Kanchan PATEL, DIA Associate Director, India-Singapore OperationsEmail: kanchan.patel@DIAglobal.org Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)